TNFRSF18 and central nervous system cancer: Subsequently, we investigated the effects of two different GITR agonists in combination with TGF-β inhibition in syngeneic glioma models, both in vitro and in vivo, laying the groundwork for further exploration of this novel dual immunotherapeutic strategy in glioblastoma.